Neovasc Inc. Reports Second Quarter 2009 Financi...(------------------------------- -----...),Health

Date:8/19/2009

------------------------------- ------------------------------------------------------------------------- June 30, December 31, 2009 2008 ------------------------------------------------------------------------- ASSETS CURRENT Cash and cash equivalents $ 1,340,471 $ 2,498,439 Accounts receivable 441,783 470,200 Inventory 526,150 341,564 Prepaid expenses and other assets 58,520 52,356 ------------------------------------------------------------------------- 2,366,924 3,362,559 RESTRICTED CASH AND CASH EQUIVALENTS 50,000 50,000 RETIREMENT ASSETS 8,320 8,320 PROPERTY AND EQUIPMENT 1,344,730 1,399,644 ------------------------------------------------------------------------- $ 3,769,974 $ 4,820,523 ------------------------------------------------------------------------- ------------------------------------------------------------------------- LIABILITIES CURRENT Accounts payable and accrued liabilities $ 1,159,173 $ 1,218,405 Current portion of long-term debt 39,650 20,635 ------------------------------------------------------------------------- 1,198,823 1,239,040 LONG-TERM DEBT 377,279 418,612 RETIREMENT LIABILITIES 8,964 8,964 -------------------------------------------------------------------------
'/>"/>

SOURCE Neovasc Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related medicine news :

1. Neovasc Reports Development Progress, Streamlined Operations and Issuance of Options
2. Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results
3. Neovasc Announces Agreement With LeMaitre Vascular for Exclusive Distribution Rights to its Biological Vascular Strips
4. Neovasc Receives CE Mark Approval for Peripatch(TM) Aegis Staple Line Reinforcement Product
5. Neovasc to Raise $2 Million in Non-Brokered Private Placement
6. Neovasc Inc. Reports Year 2008 Financial Results
7. Neovasc Completes $2 Million Non-Brokered Private Placement
8. Positive Results for Ophthotechs Novel Therapy for Wet AMD - Study of Anti-PDGF and Anti-VEGF Therapy Shows Significant Neovascular Regression and Enhanced Visual Outcome
9. Neovasc Inc. Reports First Quarter 2009 Financial Results
10. Neovasc Inc. Postpones Plans for U.S. Listing to Focus Funds on Commercializing Its Reducer Device for Refractory Angina
11. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites